This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Getty Images milla1cf Mon, 02/12/2024 - 15:22 February 12, 2024 — Sensome , a company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today enrollment of the first patients into a feasibility clinical study using the Clotild Smart Guidewire in peripheralarterydisease (PAD).
The Neuroguard Integrated Embolic Protection (IEP) system is an experimental treatment for carotid artery stenosis, also known as carotid arterydisease, a condition in which fatty-waxy deposits known as plaque builds up and blocks the normal flow of blood in the large arteries on either side of the neck.
Specifically, this genetic factor was found to lower the risk of type 2 diabetes by 46.5%, coronary heart disease by 37.5%, ischemic stroke by 35.4%, cardiac-related mortality by 28.6%, heart failure by 28.2%, transient ischemic attack by 24%, atrial fibrillation by 15.2%, peripheralarterydisease by 0.3%, and hypertension by 0.3%.
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionMycotic aneurysms of paraspinal arteries are a rare finding. Furthermore, knowledge regarding the management of paraspinal mycotic aneurysms and the efficacy of endovascular repair of these lesions is scarce.⁴MethodsWe
AF is associated with an increased risk of death as well as multiple adverse outcomes, including stroke, cognitive impairment or dementia, myocardial infarction, sudden cardiac death, heart failure (HF), chronic kidney disease (CKD), and peripheralarterydisease (PAD).
Stroke, Volume 56, Issue Suppl_1 , Page A136-A136, February 1, 2025. Introduction:The ARCADIA trial found no benefit of anticoagulation for secondary stroke prevention in patients with cryptogenic stroke and evidence of atrial cardiopathy. The trial screened all patients with cryptogenic stroke, regardless of infarct topography.
Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels, such as coronary heart disease, cerebrovascular disease (e.g., stroke), peripheralarterialdisease, congenital heart anomalies, deep vein thrombosis, and pulmonary embolism.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content